arrow
S

Seth E. Karol

st jude childrens research hospital
H指数:24
被引数:2,378

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities

第二十一届国际“蓬特迪莱诺”儿童急性淋巴细胞白血病研讨会报告:进展与新兴机遇

2026-08-190
PRE
Traumatic lumbar puncture at diagnosis in children and adolescents with acute lymphoblastic leukemia

儿童和青少年急性淋巴细胞白血病患者诊断时的创伤性腰椎穿刺

Leukemia
IF13.4
2026-07-310
PRE
Association of neuropathy, sarcopenia and physical function in acute lymphoblastic leukemia survivors with chemotherapy alone

化疗单用的急性淋巴细胞白血病幸存者中周围神经病、肌少症与躯体功能的关系

2026-03-260
OAAI
Recognition, prevention, and management of adverse events associated with asparaginase/pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel

急性淋巴细胞白血病成人患者应用天冬酰胺酶/聚乙二醇化天冬酰胺酶治疗相关不良事件的识别、预防与管理:专家共识

2025-12-012
OAAI
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment

使用整合全基因组与转录组测序作为儿科及青少年急性髓系白血病诊断和风险评估框架的临床经验

Leukemia
IF13.4
2025-10-070
OA
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

临床药理学实施协会指南:NAT2基因型与肼屈嗪疗法

2025-09-011
OAAI
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies

ETV6::RUNX1或高超二倍体B-ALL患者在接受St. Jude Total Therapy XV/XVI研究治疗后结果

BLOOD
IF23.1
2025-01-093
PRE
Oncogenic Potential and Sensitivity to Menin Inhibitors of a Novel Fusion KAT6B::NUTM2B in Congenital Myeloid Sarcoma with Bone Marrow Involvement

原癌基因潜能及对Menin抑制剂的敏感性:一种新型融合KAT6B::NUTM2B在伴有骨髓受累的先天性髓系肉瘤中的研究

BLOOD
IF23.1
2024-11-050
PRE
Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations
2024-01-167
PRE